Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals
  6. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
585.23(c) 587.24(c) 583.72(c) 586.88(c) 586.35(c) Last
552 105 644 953 480 841 406 910 626 463 Volume
+0.34% +0.34% -0.60% +0.54% -0.09% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12 231 M - -
Net income 2021 4 984 M - -
Net cash position 2021 9 191 M - -
P/E ratio 2021 12,5x
Yield 2021 -
Sales 2022 11 250 M - -
Net income 2022 4 047 M - -
Net cash position 2022 10 760 M - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 60 720 M 60 720 M -
EV / Sales 2021 4,21x
EV / Sales 2022 4,44x
Nbr of Employees 9 447
Free-Float 82,2%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
Read more
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
07/23REGENERON PHARMACEUTICALS : RBC Raises Price Target on Regeneron Pharmaceuticals..
MT
07/20Agilent Technologies PharmDx Assay Receives Expanded Use in EU
MT
07/20REGENERON PHARMACEUTICALS : Antibody Cocktail Gets Full Approval in Japan as Tre..
MT
07/20REGENERON PHARMACEUTICALS : Japan Becomes First Country to Approve Regeneron Ant..
PR
07/19Roche's Ronapreve Treatment for Covid-19 Approved by Japan
DJ
07/19Chugai Pharmaceutical Obtains Approval for Covid Antibody Cocktail
DJ
07/19EU evaluates Sobi arthritis drug to treat COVID-19 with pneumonia
RE
07/16REGENERON PHARMACEUTICALS : Plans $1.8 Billion Expansion in Westchester County, ..
MT
07/16REGENERON PHARMACEUTICALS : AbbVie, Lilly face fresh delays in FDA approval for ..
RE
07/13GSK-Vir Biotechnology's COVID-19 Antibody Wins Distribution Nod in Italy
MT
07/13ISA Pharmaceuticals B.V. announced that it has received €26 million in fundin..
CI
07/08REGENERON PHARMACEUTICALS : Benchmark Capital Adjusts Regeneron Pharmaceuticals ..
MT
07/07REGENERON PHARMACEUTICALS : to Report Second Quarter 2021 Financial and Operatin..
PR
07/07INSIDER TRENDS : Insider at Regeneron Pharmaceuticals Converts/Exercises Derivat..
MT
07/07SILVERBACK THERAPEUTICS : Signs Supply Deal With Regeneron for Libtayo in Early-..
MT
More news
News in other languages on REGENERON PHARMACEUTICALS
07/20Résumé des principales informations économiques du mardi 20 juillet 2021
07/20PLANÈTE BOURSE : La revue de presse du mardi 20 juillet 2021
07/20Roches Covid-19-Medikament Ronapreve erhält Zulassung in Japan
07/20Roche obtient un feu vert au Japon pour son cocktail anti-Covid
07/20ROCHE : Japan lässt als erstes Land Covid-Medikamentencocktail zu
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Analysis
Intellia Therapeutics : Growth stock comeback fuels Cathie Wood's ARK funds
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 586,35 $
Average target price 638,39 $
Spread / Average Target 8,88%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS21.37%57 013
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308
BEIGENE, LTD.22.66%33 627